2022 World Conference on Lung Cancer (ePosters)-EP08.02-145. An Efficacy Analysis of Advanced Non Small Cell Lung Cancer With MET Exon 14 Skipping in the Real World

EP08.02-145. An Efficacy Analysis of Advanced Non Small Cell Lung Cancer With MET Exon 14 Skipping in the Real World

Pdf Summary

In this study, the efficacy of crizotinib, a tyrosine kinase inhibitor, in treating non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations was evaluated in a real-world setting. A total of 21 patients were enrolled in the study and treated with crizotinib, with evaluations conducted bimonthly.<br /><br />The results showed that treatment with crizotinib was associated with improved survival in patients with MET exon 14 mutations. The median progression-free survival was 7.87 months, and the median overall survival was 41 months. Among the 20 patients who were evaluated for response, 35% had a partial response, 60% had stable disease, and 5% had progressive disease. The overall response rate was 35%.<br /><br />The baseline characteristics of the patients included in the study were also analyzed. Most patients were male (76.19%) and had a smoking history (76.19%). There was an equal distribution between those with a family history of cancer (47.62%) and those without (52.38%). Pleural metastasis was present in 28.57% of patients. The majority of patients started crizotinib treatment in the second line (38.10%) or in subsequent lines of therapy (33.33%).<br /><br />These findings provide real-world evidence supporting the efficacy of crizotinib in treating NSCLC with MET exon 14 skipping mutations. The study demonstrates that crizotinib can improve survival in patients with this genetic alteration. Further research and larger studies are needed to validate these results and determine the optimal treatment strategies for patients with MET exon 14 skipping mutations.

Asset Subtitle

Fei Teng

Meta Tag

Speaker Fei Teng

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

crizotinib

tyrosine kinase inhibitor

non-small cell lung cancer

NSCLC

MET exon 14 skipping mutations

real-world setting

efficacy

progression-free survival

overall survival

response rate